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Abstract Newborn screening for severe primary immunode-
ficiencies (PID), characterized by T and/or B cell lymphope-
nia, was carried out in a pilot program in the Stockholm
County, Sweden, over a 2-year period, encompassing 58,834
children. T cell receptor excision circles (TREC) and kappa-
deleting recombination excision circles (KREC) were mea-
sured simultaneously using a quantitative PCR-based method
on DNA extracted from dried blood spots (DBS), with beta-
actin serving as a quality control for DNA quantity.
Diagnostic cutoff levels enabling identification of newborns
with milder and reversible T and/or B cell lymphopenia were
also evaluated. Sixty-four children were recalled for follow-up
due to low TREC and/or KREC levels, and three patients with
immunodeficiency (Artemis-SCID, ATM, and an as yet un-
classified Tcell lymphopenia/hypogammaglobulinemia) were
identified. Of the positive samples, 24 were associated with
prematurity. Thirteen children born to mothers treated with
immunosuppressive agents during pregnancy (azathioprine
(n = 9), mercaptopurine (n = 1), azathioprine and tacrolimus
(n = 3)) showed low KREC levels at birth, which spontane-
ously normalized. Twenty-nine newborns had no apparent
cause identified for their abnormal results, but normalized
with time. Children with trisomy 21 (n = 43) showed a lower
median number of both TREC (104 vs. 174 copies/μL blood)
and KREC (45 vs. 100 copies/3.2 mm blood spot), but only
one, born prematurely, fell below the cutoff level. Two chil-
dren diagnosed with DiGeorge syndrome were found to have
low TREC levels, but these were still above the cutoff level.
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This is the first large-scale screening study with a simulta-
neous detection of both TREC and KREC, allowing identifi-
cation of newborns with both T and B cell defects.
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Introduction
The purpose of neonatal screening is the early recognition of
treatable, mostly genetically determined diseases that manifest
with a high rate of morbidity and mortality. Mass screening of
newborn infants with dried blood spots (DBS) started in the
early 1960s based on a method developed by Guthrie and Susi
for diagnosing phenylketonuria [1]. Peripheral blood from a
heel stick was blotted onto filter paper (referred to as BGuthrie
card^) at 3 to 5 days after birth, dried, and sent by mail to
centralized laboratories for analysis.
The US congress decided in 2006 to include 29 core and 25
secondary disorders in its newborn screening program based
on a priority list of disorders. In recent years, a number of
additional disorders, among them severe combined immuno-
deficiency (SCID), have been included in this list, based on
the well-recognized Wilson and Jungner criteria [2]. In
Sweden, neonatal screening with DBS was initiated in 1965
and today, a total of 24 disorders are included in the program.
Genetically determined disorders of immunity are com-
monly referred to as primary immunodeficiencies (PID) and
were first recognized clinically over 60 years ago with the
identification of X-linked agammaglobulinemia (XLA) [3].
Today, the group of PID includes more than 250 distinct enti-
ties, which are divided into Tcell deficiencies, B cell deficien-
cies (the predominant group), combined T and B cell deficien-
cies, complement defects, and granulocyte defects [4].
Primary immunodeficiencies as a group are not rare dis-
eases, but should be considered in all patients presenting with
severe, atypical, or recurrent infections. The overall preva-
lence is unknown, but varies greatly (from 1:600 for IgA de-
ficiency, 1:20,000 for common variable immunodeficiency,
1:50,000 for SCID, and 1:100,000 for XLA) [4] and refer-
ences therein [5]. The estimated incidence of severe forms of
PID, which require immediate attention, is variable in differ-
ent populations, but would be expected to be in the order of 5–
10 per 100,000 live births.
In 2005, Chan and Puck published a seminal paper, describing
the T-cell receptor excision circle (TREC) assay as a tool for
large-scale screening for SCID and other T cell lymphopenias
[6]. T cell receptor genes are normally edited during T cell dif-
ferentiation, and the deleted fragments are circularized and do not
undergo further replication in dividing cells. Thus, TRECs are a
marker of recently formed T cells. The TREC copy number can
be determined using a quantitative PCR-based method using
DNA extracted from routinely collected DBS. The TREC assay
was implemented in the state of Wisconsin in 2008 [7] and its
inclusion in the newborn screening programs in the USA was
recommended in 2010. Currently, 38 states are screening for
SCID using the TREC assay, with the remaining 12 states due
to commence in 2017 (Jeffrey Modell Foundation, http://www.
info4pi.org/).More than threemillion newborns have been tested
to date [8]. The results show a frequency of SCID of 1/58,000
children (overall 1/7300 with clinically relevant forms of T cell
lymphopenia) and a high survival rate (92 %) after treatment.
Congenital B cell lymphopenia can be identified by screen-
ing for kappa-deleting recombination excision circles
(KREC), the circular by-product of B cell immunoglobulin
kappa gene rearrangement [9]. Patients with severe forms of
B cell deficiency such as XLA are easily identified by the
KREC assay [10] and are treated with regular gammaglobulin
infusions, thereby allowing a near to normal life. Furthermore,
it has been shown that delayed-onset forms of SCID and other
severe forms of PID that present with normal T cell numbers
and TREC levels above cutoff in newborn screening programs
may be identified using a combined TREC and KREC screen-
ing approach [11].
We thus initiated a screening program for all newborns in
the county of Stockholm in Sweden using a combined TREC
and KREC assay [12]. We previously analyzed 10,058 sam-
ples as part of a feasibility study, and one XLA patient was
identified (Bruton tyrosine kinase gene mutation, c.1480C>T,
p.Gln494Ter), thus demonstrating proof of principle of the
combined screening approach [12]. Although a small cohort
of Spanish newborns have been screened using the combined
TREC/KREC assay [13], this represents the first large-scale
prospective study where both T and B cell defects
(lymphopenia) can be identified and the results of the first
2 years of the screening program are reported here.
Materials and Methods
Sampling
We carried out a study encompassing samples from all children
born in the Stockholm County from November 15, 2013 to
November 15, 2015, searching for children with T and B cell
lymphopenia, in order to identify those with severe forms of
PID. A total of 58,834 samples were analyzed. For 24 addition-
al infants, the parents chose not to participate in the study. The
blood sample was collected onto Whatman 903 filter paper as
soon as possible after 48 h of age, presently at a mean age of
2.8 days, and was then mailed to the laboratory. The average
age at recall for a positive screening result was 6 days.
The regional ethical board in Stockholm approved the
study (Ethical permit 2013/414-31/4).
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TREC/KREC Screening Assay
The TREC/KREC newborn screening assay described previ-
ously [12] was utilized, with minor technical modifications.
Briefly, DNA was extracted from single 3.2-mm punches of
the original DBS in a 96-well format, and quantitative triplex
real-time qPCR for TREC, KREC, and beta-actin (ACTB)
was performed using a ViiA7 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) on DNA eluates
as previously described [12]. The qPCR procedure was opti-
mized using custom reagents provided by Affymetrix (Santa
Clara, CA, USA). TREC and KREC levels were determined
per 3.2-mmpunch. Amplification of ACTBwas used to assess
that a sufficient quantity of DNA was extracted from each
DBS, but this was disregarded if TREC and KREC copy
numbers were above the cutoff level. The samples were ini-
tially analyzed once, and if the value was below the cutoff,
they were reanalyzed in duplicate. Samples in which TREC
and/or KREC levels were below cutoff in association with a
reduction in ACTB copy number were considered inconclu-
sive. Cutoff levels for TREC/KREC were adjusted during the
study based on the yield of positive samples.
Genetic Characterization of Patients with Low
TREC/KREC Levels
For the three children with suspected PID, whole exome se-
quencing (WES) was performed, followed by confirmatory
Sanger sequencing. DNA purification, library preparation,
read mapping, variant determination, and analysis of WES
data were performed as described previously [14, 15].
Sequences were generated as 90-bp pair-end reads and aligned
to the human genome reference (UCSC hg 19 version, build
37.1) by using the SOAP aligner (soap 2.21) software.
Duplicated reads were filtered out and only uniquely mapped
reads were kept for subsequent analysis. The SOAPsnp (ver-
sion 1.03) software was subsequently used with default pa-
rameters to assemble the consensus sequence and call geno-
types in target regions. For single nucleotide polymorphism
(SNP) quality control, low-quality SNPs that met one of the
four following criteria were filtered out: (1) a genotype quality
of less than 20, (2) a sequencing depth of less than 4, (3) an
estimated copy number of more than 2, and (4) a distance from
the adjacent SNPs of less than 5 bp. Small insertions/deletions
were detected by using the Unified Genotype tool fromGATK
(version v1.0.4705) after alignment of quality reads to the
human reference genome using BWA (version 0.5.9-r16).
Statistical Analyses
Statistical analyses were performed using GraphPad Prism
Version 6.0 (GraphPad Software, San Diego, CA). Given the
nonparametric distribution of the data, the Mann-Whitney U
test was used for group comparison analyses, and the
Spearman correlation coefficient was calculated for correla-
tion analyses. Differences were considered statistically signif-
icant when the p value was less than 0.05.
Results
Screening Overview
In total, 58,834 newborns were screened. Samples with TREC
and/or KREC copies below the cutoff values were considered
Babnormal^ (positive), whereas those that also had reduced
ACTB copy numbers were considered to be Binconclusive.^
Initially, 572 samples were found to be either abnormal
(positive) or inconclusive (n = 399 and n = 173, respectively)
(Fig. 1). After repeat testing on the original DBS, 64 abnormal
(positive) samples remained, i.e., 99.9 % were considered
normal and were not evaluated further. A total of 13 patients
were recalled for repeat sampling due to poor quality of their
initial DBS sample.
The definition of Blow^ levels of TREC and KREC copies
will determine how many samples are considered positive.
The dilemma is to avoid unnecessary recalls while still cap-
turing all patients with a severe form of PID (i.e., SCID and
XLA), as well as additional patients with profound distur-
bance of T and B cell homeostasis at birth. Three different
cutoff levels for recall were used during the study as the limits
were adjusted based on the number and outcome of the recalls.
During the first period, a cutoff level of 15 copies/3.2 mm
blood spot or below for TREC and 10 copies/3.2 mm blood
spot blood or below for KREC was applied. In total, 16,582
children were screened and 35 were considered to have a
positive result. However, the vast majority recovered sponta-
neously (Supplementary Table 1) and the cutoff was subse-
quently lowered to a TREC level of 8 copies/3.2 mm blood
spot or below and a KREC level of 4 copies/3.2 mm blood
spot blood or below. Another 28,298 children were screened
during this period and 11 were found to be positive, among
them PID patients 1 and 2. As these cutoffs were ultimately
considered too stringent, they were finally changed to a TREC
level of 10 copies/3.2 mm blood spot or below and a KREC
level of 6 copies/3.2 mm blood spot or below. Altogether,
13,954 children were subsequently screened and 18 were
found to be positive, among them PID patient 3.
The patients with TREC/KREC levels below the cutoff
(Supplementary Table 1) were referred to a pediatrician spe-
cialized in the diagnosis and management of PID. The patient
with absent TREC and KREC was immediately hospitalized
whereas in the vast majority of patients, a follow-up sample
for TREC and KREC analysis was collected within 2–
10 weeks (Table 1) depending on the clinical urgency and
gestational age. The recall was almost exclusively due to
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low KREC levels, and these patients were usually seen and
resampled at around 3 weeks of age. In the majority of cases,
the TREC/KREC values had normalized at the time of resam-
pling (Supplementary Table 1) and only three patients (ap-
proximately 1/20,000) were referred for flow cytometric
(fluorescence-activated cell sorting, FACS) analysis and ge-
netic work-up (WES). In the majority of recalled patients,
follow-up investigation with FACS analysis was not per-
formed, as it was not deemed clinically relevant. To date, none
of the infants in whom KREC/TREC levels normalized have
subsequently developed features of PID.
Abnormal (Positive) TREC/KREC Results
Altogether, 64 children were recalled for follow-up due to low
TREC and/or KREC levels and three patients with severe
primary immunodeficiency were identified (Supplementary
Table 1). Among the positive samples (Fig. 2), several infants
had more than one potential etiological factor contributing to
their low TREC and/or KREC levels. A total of 24 infants
were premature, including one with trisomy 21 and 11 were
a twin or triplet. Furthermore, 13 infants were born to mothers
receiving immunosuppressive therapy. Twenty-nine had no
apparent cause identified and the TREC/KREC levels in the
children tested (n = 27) normalized with time. Resampling
was declined for four of the 64 children recalled.
The 13 children born to mothers who were treated with
immunosuppressive agents during pregnancy (azathioprine
(n = 9), mercaptopurine (n = 1), azathioprine and tacrolimus
(n = 3)) showed low KREC levels at birth, which however
spontaneously normalized after 2–10 weeks. Two children
from a mother treated with azathioprine, born almost 2 years
apart, both showed low KREC at birth.
Other Conditions Influencing the Screening Result
Children with trisomy 21 (n = 43) showed a lower median
number of both TREC (104 vs. 174 in the total material) and
KREC (45 vs. 100), but only one child, born prematurely, fell
below the cutoff levels applied at the time of testing. Two
children were diagnosed with DiGeorge syndrome in the
Department of Clinical Genetics, and both had a low TREC
level but these were still above the cutoff level at the time of
testing.
Among the 3457 infants born prematurely (prior to
37 weeks gestation), 24 screened positive with low TREC
(n = 12) , KREC (n =11) l eve l s , o r bo th (n = 1)
(Supplementary Table 1). Although T cells appear to mature
late in fetal life, TREC and KREC levels were surprisingly
Bnormal^ in the majority of children, even at very low gesta-
tional ages (Table 2), albeit as a group they were still signifi-
cantly below the levels in children born at term (p < 0.0001,
Mann-Whitney U test) (Fig. 3).
A total of 896 twin pairs and 16 triplet sets (n =1840) were
identified in the cohort, and the TREC and/or KREC values
differed markedly between the newborns in both those sib-
lings with low levels (Table 3) and in those with values within
the normal range (Fig. 4).
To the best of our knowledge, no patients with severe PID
characterized by absent T or B cells at birth have been missed
to date among those infants included in the screening
program.
PID Patients
Three patients were found to have repeatedly low levels of both
TREC and KREC (n= 1) or TREC alone (n = 2) (Table 1) and
Fig. 1 Summary of all newborn screening results between 15 November 2013 and 15November 2015. *Two infants had low TREC levels, and one had
low TREC and KREC levels. **See Fig. 2
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were considered to have a severe immunodeficiency disorder.
The first patient had a homozygous splice-site mutation in
Artemis (DLCLRE1C c.333+2T>G) with absent protein expres-
sion and underwent a successful stem cell transplantation at the
age of 2 months. The second child shows clinical features of
ataxia-telangiectasia and carries compound heterozygous muta-
tions in ATM, where the mother contributed a c.3673C>T muta-
tion resulting in a stop codon (p.Gln1225Ter) and the father
contributed a c.8653_8654insT mutation resulting in a
Val2886CysfsTer10 mutation. The third child was found to have
T cell lymphopenia and hypogammaglobulinemia, but genetic
analysis (including whole genome sequencing) has not as yet
revealed any causativemutation in known PID genes. The results
of immunological investigations for the three PID patients iden-
tified are given in Supplementary Table 2.
Discussion
Since 2008, TREC analysis has been the method of choice for
screening of newborns for severe forms of primary T cell
lymphopenia [6, 7, 16], a method that will capture most, but
not all, children with SCID (exceptions being patients with
mutations in ZAP70 [17, 18], MHC class II [19–21], and
ADA (delayed-onset disease [11]). We subsequently devel-
oped a triplex method that also includes KREC analysis to
assess for potential B cell lymphopenia in DBS samples.
This method can successfully identify patients with XLA
[12], selected patients with delayed-onset adenosine deami-
nase deficiency (ADA) [11], Nijmegen-breakage syndrome
(NBS) [12], and purine nucleoside phosphorylase (PNP) de-
ficiency [22]. The combined assay has recently also been used
to screen patients with SCID [23, 24], ATM [12, 25], Wiskott-
Aldrich syndrome (WAS) [26], DiGeorge syndrome [27–29],
and trisomy 21 [30], and it has been suggested to be included
in routine screening of newborns for primary immunodefi-
ciency [31–34]. KREC levels have also been used to monitor
immune reconstitution after bone marrow/stem cell transplan-
tation [35–37].
Ours is the largest study to date using a combined
TREC/KREC assay for newborn screening. One SCID patient
was identified (and successfully transplanted) in our cohort of
58,000 infants, comparable with the data published by Kwan
et al. on a very large US cohort [8]. One patient with ATM was
also identified. This disorder is very rare, with an estimated
incidence of 1 in 200,000 according to recent figures from the
Fig. 2 Characteristics of the 64
infants with abnormal screening
results recalled for repeat testing.
*Azathioprine (n = 9),
mercaptopurine (n = 1),
azathioprine + tacrolimus (n = 3).
**One infant who was premature
also had trisomy 21
Table 1 Serial TREC and KREC levels in PID patients with abnormal screening test results
TREC copies/3.2 mm blood spot KREC copies/3.2 mm blood spot
Case Sex Gestational
age (weeks)
Diagnosis Result 1 Result 2 Result 3 Result 4 Result 1 Result 2 Result 3 Result 4
















































a Tcell lymphopenia and hypogammaglobulinemia. At follow-up at 15months of age, the child’s hypogammaglobulinemia had resolved but a persistent
idiopathic CD3+ T cell lymphopenia (absolute CD3+ count = 0.9 × 109 /L) was evident
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USA [38]. It will be interesting to determine if this finding is due
to serendipity or if the disease is more frequent in Scandinavia.
Our third patient showed a T cell lymphopenia of unknown
cause. Such cases have been previously described in studies in
the USAwith incidences varying between 3 and 4 per 100,000
children in different states and with a predicted incidence of 1 in
160,000 in a British study (Professor Bobby Gaspar, Great
Ormond Street Hospital, personal communication). Recently,
during the third year of screening, yet another SCID patient
(ADA deficiency) and a patient with severe T cell lymphopenia
have been identified.
The number of referrals for flow cytometric analysis in our
cohort was low (approximately 1:20,000), markedly lower than
that reported in the US study of Kwan et al. [8] (ranging from
1/735 to 1/7500 in the different states). This is a reflection of the
strict resampling strategy that was applied to children with low,
Table 2 Mean TREC and KREC
levels at different gestational ages Gestational
age (weeks)
Infants (n) Mean TREC level
(copies/3.2 mm blood spot)
Mean KREC level
(copies/3.2 mm blood spot)
20 1 262 139
21 2 97 180
22 3 84 97
23 23 53 52
24 31 68 58
25 38 64 70
26 50 71 62
27 58 89 65
28 53 93 76
29 97 114 91
30 97 139 110
31 122 134 99
32 199 146 90
33 283 139 87
34 390 142 93
35 663 153 97
36 1347 156 103
Total 3457
































KREC levels according to gestational age
**** p < 0.0001
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TREC levels according to gestational age
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**** p < 0.0001**** ****





Fig. 3 Comparison of TREC levels (a) in infants born prior to 25 weeks,
between 25 and 36 weeks, and at term (≥37 weeks) gestation.
Comparison of KREC levels (b) in infants born prior to 27 weeks,
between 27 and 36 weeks, and at term (≥37 weeks) gestation. Each
point represents one infant and the number of infants in each group is
indicated. The horizontal blue line indicates the mean value of all
samples. The dashed horizontal red line represents the cutoff value for
TREC (<10 copies/3.2 mm blood spot) and KREC (<6 copies/3.2 mm
blood spot) levels, respectively. ****p < 0.0001, Mann-Whitney U test
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but not absent TREC or KREC levels. These results also indicate
that the addition of KREC testing to the TREC assay in a new-
born screening program does not critically drive the demand for
second tier testing nor does it increase the fiscal impact of the test
itself due to the minimal additional cost of multiplexing.
Prematurity has been considered a predisposing factor for
low TREC numbers in studies in American infants [8]. The
TREC and KREC levels in our study did show a downward
trend with decreasing gestational age, although in the vast
majority, the levels were above the cutoff, even in markedly
Table 3 Discrepant TREC and
KREC levels in twin and triplet
















1aa 38 Female TW I 3 1 18 Deceased
1b 38 Female TW II 3 138 161
2a 34 Male TW I 2 51 259
2ba 34 Male TW II 2 13 92
3aa 25 Female TW I 0 5 25 Deceased
3b 25 Female TW II 0 19 178
4a 29 Male TR I 3 20 42
4ba 29 Female TR II 3 15 29
4c 29 Female TR III 3 70 56
5a 29 Male TW I 2 76 130
5ba 29 Male TW II 2 5 16
6a 27 n.a TR I Deceased
6b 27 n.a TR II Deceased
6ca 27 Male TR III 3 5 28
7aa 38 Female TW I 3 149 6
7ba 38 Female TW II 3 132 5
8a 32 Female TW I 2 77 40
8ba 32 Female TW II 2 13 5
9a 24 Male TW I 2 16 68
9ba 24 Female TW II 2 9 13
10a 23 n.a TW I Deceased
10ba 23 Female TW II 2 7 11
TW twin 1, TR triplet, n.a. not available
a Recalled twin/triplet





Correlation between TREC levels within each twin pair




































Correlation between KREC levels within each twin pair
































Fig. 4 Correlation between TREC (a) and KREC (b) levels within all
896 twin pairs. Each point represents one twin pair, where the TREC
value for twin 1 (x axis) is plotted against the TREC value for twin 2 (y
axis) (a). KREC levels for each pair are similarly depicted (b). Overall,
there was poor correlation between specimen pairs, with a calculated
Spearman correlation coefficient (Rs) of 0.6 for TREC and 0.57 for
KREC (p < 0.0001)
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premature infants. This notion was also recently supported
[13] in a small Spanish cohort of newborns.
Twins and triplets were markedly overrepresented among the
positive samples (n = 11/64), potentially reflecting prematurity in
themajority of cases (n= 8/11). There was a notable difference in
TREC and KREC levels within twin pairs returning normal
screening results. Although information regarding zygosity was
not available, it is expected that one in four pairs is monozygotic
and therefore genetically identical, and this observation will thus
be further investigated in the future studies.
Thirteen children with low KREC levels were born to 12
mothers who had been treated with azathioprine during pregnan-
cy, three of whomwere concomitantly receiving tacrolimus. Two
children born to the same azathioprine-treated mother, 2 years
apart, both had low KREC levels. Low KREC levels were also
recently noted by de Felipe et al. [13] in a small cohort of Spanish
children born to mothers treated with azathioprine. As azathio-
prine may cross the placenta (and is mutagenic), it is generally
contraindicated during pregnancy unless used for treatment of
severe disease. As B lymphocytes are markedly more sensitive
to drug-induced apoptosis than T lymphocytes [39], the selectiv-
ity for a reduction in KREC copies alone is not surprising.
We anticipated that some infants with trisomy 21 would
screen positive since they may have low B cell and/or T cell
production [30]. However, only one of the 43 infants screened
during the 2-year period had a KREC level below cutoff,
although infants with trisomy 21 had generally lower levels
than those in the general newborn population. In Sweden, the
estimated frequency of chromosome 22q deletions is around
1/4000, suggesting that some 14–15 children in the screened
cohort would suffer from this form of PID. However, less than
10 % of chromosome 22q deletion patients had pronounced T
cell lymphopenia (measured as low TREC levels) and an ad-
ditional 5–10% had levels close to the cutoff. Thus, we would
have expected only one to two children to be identified in our
tested cohort, which is not statistically different from the pres-
ent result (no child identified).
Most of the children in our study were recalled due to low
KREC levels. This was expected, as we did not knowwhat the
Btrue^ cutoff level for children with XLAwould be and thus
applied a fairly large safety margin. Ongoing studies in our
laboratory, analyzing KREC levels in a large cohort of chil-
dren with mutation proven XLA, may allow further adjust-
ment of the recall level of KREC, thus reducing the efforts
and costs associated with Bfalse^ positive results.
Newborn screening formetabolic diseases has undergonema-
jor changes during the past decades with inclusion of numerous
very rare diseases in the program. We anticipate a similar devel-
opment in the PID screening field where the KREC may ulti-
mately be added to the TREC assay currently used in several
national screening programs. The decision regarding implemen-
tation of TREC vs. combined TREC/KREC screening can be
guided by considering the advantages and disadvantages of each
screening approach. The advantages for adding KREC screening
include the identification of children with XLA, late onset ADA,
some patients with NBS, and other selected forms of PID whose
disease may be undetected by TREC screening alone [8, 23, 40].
In addition, it may assist in distinguishing patients with SCID
caused by deficiency in the production of T as well as B cells or
only T cells, thus aiding in the diagnostic process. On the nega-
tive side, increased costs associated with the additional KREC
assaymay be considered a disadvantage of the combined screen-
ing strategy. With the possibility to multiplex PCR reactions, the
individual cost for additional screeningmarkers such asKREC in
an existing TREC screening system is negligible (<€0.10 per
newborn), but associated costs incurred in follow-up and further
testing for infants with abnormal screening results should also be
considered. However, it should be noted that the recall rate using
the combined TREC/KREC assay is similar to that of TREC
screening alone [8], with a lower rate of follow-up FACS studies
than in other published studies to date.
As markers for other genetic diseases have been proposed
which can be multiplexed with the TREC/KREC system, fu-
ture efforts may be focused on the extension of existing new-
born screening tests for PID [26]. This may potentially include
complement deficiencies (using DBS eluates as described by
Janzi et al. [41] for C3 deficiencies and Hamsten et al. [42] for
C2 deficiencies) and granulocyte defects, thus allowing cov-
erage of a majority of the primary immunodeficiency diseases.
Targeted exome sequencing or even whole genome sequenc-
ing of newborns may ultimately be considered, which could
lead to identification of additional defects of immunity and a
large number of other inherited, potentially fatal diseases.
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